洛贝林通过减轻炎症,恢复屏障功能,调节肠道微生物群与代谢物相互作用,改善小鼠DSS诱导的性结肠炎
Min Chang1,2, Fengping Liu1, Junhui Lu3
1The First Clinical Medical College, Shanxi Medical University, Taiyuan, China.
Frontiers in microbiology
|December 15, 2025
概括
洛贝托林 (LBT) 通过减少炎症和氧化应激,有效治疗性结肠炎 (UC). 这种天然化合物还改善了肠道屏障功能和微生物平衡,为UC提供了有前途的多目标疗法.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,治疗选择有限.
- 现有的UC疗法有副作用和复发问题,需要新的治疗方法.
- 洛贝林 (LBT),一种天然的多乙烯糖化物,正在研究其治疗潜力.
研究的目的:
- 在硫酸 (DSS) 诱导的大肠炎的小鼠模型中研究洛贝林 (LBT) 的保护作用.
- 阐明LBT在缓解UC病理方面的潜在多目标机制.
主要方法:
- 使用了一种DSS诱导的大肠炎小鼠模型,小鼠接受了不同剂量的LBT治疗.
- 评估了临床和组织学参数,炎症/氧化应激标志物,上皮屏障蛋白,肠道微生物群和代谢物.
- 使用的技术包括ELISA,西方涂抹,16SrRNA测序,GC-MS和UHPLC-MS/MS.
主要成果:
- LBT治疗显著改善了结肠炎的临床症状,包括体重和结肠长度.
- LBT降低了关键的炎症性细胞因子 (TNF-α,IL-6,IL-1β) 和氧化应激标志物.
- 经过LBT增强了上皮屏障完整性,使肠道微生物群正常化,增加了短链脂肪酸 (SCFA),并调节了宿主代谢.
结论:
- 洛贝林显示出对DSS诱导的性结肠炎具有显著的保护作用.
- LBT通过多个目标起作用,包括减少炎症,氧化应激,改善肠道屏障功能.
- LBT显示出作为性结肠炎的安全和有效的多目标治疗剂的潜力.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
598
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
598
01:29Drugs for Treatment of Ulcerative Colitis in IBD
424
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
424